Auxilium Pharmaceuticals has announced that it will be purchasing biotech firm QLT for an estimated $345 million. The companies will be combined, and the remaining shell of QLT will be named “New Auxilium.” This move sets the company up to attain QLT’s new experimental eye drug products for its portfolio.
QLT primarily produces ophthalmology treatments for inherited retinal diseases. QLT’s leading treatment, synthetic retinoid, is a drug that replaces a key chemical component in the eye that is critical to visual functioning. The diseases treated by synthetic retinoid are caused by genetic mutations that adversely affect the availability of that key component. Adrian Adams, the CEO of Auxilium, released a statement on the acquisition. “Building on Auxilium’s strong foundation and commercial expertise, the merger with QLT represents a unique opportunity to accelerate our desired strategic transformation into a leading, diversified North American specialty biopharmaceutical company. We are creating what we believe is a more competitive and efficient platform to capitalise on greater market opportunities and position Auxilium to deliver meaningful value for shareholders while enhancing our ability to invest in and offer innovative products that make a difference in the lives of underserved patients,” he said.
This article has been extracted from http://www.bioresearchonline.com, please click on this link to read the article in fullhttp://www.bioresearchonline.com/doc/auxilium-pharmaceuticals-announces-purchase-of-biotech-qlt-0001
Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:
ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.
With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.